Algernon is a Canadian clinical stage drug development company investigating multiple drugs with global unmet medical needs. Algernon has active research programs for idiopathic pulmonary fibrosis (“IPF”) with chronic cough, chronic kidney disease, and a psychedelic program investigating a proprietary form of DMT for stroke. Two of Algernon’s lead drugs are based on drug repurposing and the third compound is a naturally occurring psychedelic drug.
Drug repurposing offers several benefits over traditional drug development including a reduction in investment and risk (repurposed compounds have a much lower risk of failing in human trials as a result of safety issues), shorter research periods and a longer active patent life. Our program specifically investigates compounds that have never been approved in the U.S. or Europe.
We protect our lead compounds with method of use, dosing, and new formulation patents, as well as composition of matter patents that include derivatives and analogues. The Algernon model is highly capital efficient, and the company has assembled an experienced management team, a globally recognized medical and scientific advisory board, and a business advisory board.
Algernon Pharmaceuticals Inc. is a billboard sponsor of Streetwise Reports and paid a fee for this company profile page.
Please refer to the important disclosures below for additional details.
Algernon Pharmaceuticals Inc. has received a U.S. patent for a ground-breaking new Non-Alcoholic Steatohepatitis (NASH) drug under investigation, and is developing another for refractory chronic cough (RCC). Click here to read how the company is repurposing these two treatments with drugs that have a known safety history.
Algernon Pharmaceuticals Inc. and its subsidiary Algernon NeuroScience have reached a new milestone in a clinical trial investigating the psychedelic drug DMT for the treatment of brain injuries. Click here to learn more about new applications for psychedelics.
Treating traumatic brain injury with alternative pharmaceuticals is delicate work. Now one Canadian firm has enlisted the help of former National Football League Neurological Player Care Safety Director Dr. David Brody.
Technical analyst Clive Maund reviews Algernon Pharmaceuticals Inc.'s 6-month, 3-year, and 9-year charts to tell you whether you should be interested in this pharma company.
Clinical-stage Algernon Pharmaceuticals' multiple pipelines include testing a psychedelic for the treatment of stroke, and testing other drugs for idiopathic pulmonary fibrosis and chronic kidney disease.
Algernon Pharmaceuticals has entered into a clinical trial agreement with Yale and caught expert Clive Maund's attention. In light of this, Maund reviews the company's chart to tell you when he believes you should buy it.
Expert Clive Maund reviews the 6-month and 15-month charts for Awakn Life Sciences Corp. to explain why he thinks this company's technical setup is exceptionally positive.
One small-cap pharma co. just published more good news on a possible treatment for patients suffering from idiopathic pulmonary fibrosis, a lung disease that's usually terminal. Find out why the company has more near-term catalysts and may continue to build on an 84% gain since a private placement in mid-August.
Expert Chris Temple gives his view on Algernon Pharmaceuticals stock in light of its positive results for its Phase 2a study for the treatment of idiopathic pulmonary fibrosis and chronic cough.
A Canadian hedge fund doubled its stake in a tiny biotech that demonstrated promising results in a study that used a former Sanofi drug called Ifenprodil to treat idiopathic pulmonary fibrosis and chronic cough. Find out the name of the company and why one analyst has given it a 12-month CA$25 target price — a 560% increase from the unit price in its recent placement.
After Algernon Pharmaceuticals Inc.'s Ifenprodil treatment for chronic cough was reviewed in a Phase 2 analysis, analysts at Research Capital Corp. noted that it is maintaining its Speculative Buy rating on the company.
A scientist at a junior biotech company recently conducted an additional review of the top line data from a Phase 2a study that used NP-120 to treat idiopathic pulmonary fibrosis (IPF) and chronic cough — only to learn that it treated chronic cough far better than first thought.
Vancouver-based pharmaceutical development firm Algernon Pharmaceuticals Inc. recently reported topline data from a Phase 2a trial of ifenprodil in IPF patients with chronic cough that met its endpoint and demonstrated promising initial efficacy. Research Capital Corp. advised that it is maintaining its CA$25.00/share price target and "Speculative Buy" rating on the company.
One junior biotech company that attempts to treat current health problems with older previously approved drugs, recently completed a Phase 2 study that showed promise in the treatment of idiopathic pulmonary fibrosis (IPF) and chronic cough. It moved the small company a step closer to bringing the treatment to market.
A Vancouver-based tech startup decides to protect its shareholders versus following through on an acquisition that would have ultimately created company-threatening dilution.
In the Feb. 10 episode of Streetwise Live!, Host Cyndi Edwards interviews two medical experts who discuss the need for a new stroke treatment, explain why today's stroke treatments are so limited and express their excitement around what Algernon Pharmaceuticals is testing with DMT.
AlphaNorth Asset Management was recently recognized as the Number One equity hedge fund in Canada at the 2021 Alternative IQ Canadian Hedge Fund Awards due to its 5-year average investment return of 40.35%. Streetwise Reports sat down with the firm's co-Founder Steven Palmer to discuss some of the firm's recent investments and emerging opportunities for 2022.
Algernon Pharmaceuticals plans to be the world's first company to test the psychedelic drug DMT in stroke patients, and it's close to achieving its goal.
Drug re-purposing co. Algernon Pharmaceuticals Inc. is actively reinventing itself. The firm's leading therapeutic candidate NP-120 (Ifenprodil) is currently being evaluated in a Phase 2 trial for IPF and chronic cough, and the company is now moving forward with a revolutionary new use for DMT to treat ischemic stroke.
During Streetwise Live! on Jan. 27, 2022, representatives of Algernon Pharmaceuticals discussed the use of the psychedelic DMT in stroke sufferers. On the broadcast were Algernon CEO Christopher Moreau and consultants to the firm, Dr. David Nutt and Dr. Rick Strassman.
Algernon Pharmaceuticals Inc. has included novel salt forms of a psychedelic drug being investigated to combat strokes in its intellectual property applications.
Algernon Pharmaceuticals is a clinical-stage, small biotech that boasts a massive pipeline of lower risk and efficient drugs. Catalysts abound with this genius repurposing company.
Canadian company Algernon Pharmaceuticals Inc. has applied to uplist to the Nasdaq in hopes of attracting U.S. investors to its mission to repurpose drugs.
Algernon Pharmaceuticals reported its acquisition of the exclusive rights from Dartmouth College for a method of use patent for use in treatment of neuroendocrine cancers expressing functional NMDA receptors.read more >
Algernon Pharmaceuticals CEO Christopher J. Moreau and Dr. David Nutt, the company's research stroke consultant, discuss Algernon's upcoming Phase 1 study of DMT for stroke.read more >
Repurposing extends a drug's reach and value, and Algernon Pharmaceuticals' strategy of finding and demonstrating new uses for existing drugs reduces risk, accelerates time to market and increases capital efficiency. read more >
Based on various positive preclinical and clinical studies, Algernon Pharmaceuticals is pursuing Ifenprodil as a potential treatment for pancreatic tumors.read more >
Algernon Pharmaceuticals reported that Ifenprodil was shown to reduce interleukin 6 in its Phase 2b/3 COVID-19 Study, which the company states may have positive implications for its use in its ongoing Phase 2 trial of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough.read more >
Have we forgotten about good Covid 19 Therapeutics? KSS MD PhD, editor-in-chief of PubBio.co, discusses three gems investors should know about.read more >
Algernon Pharmaceuticals reported expects to release topline results from the Phase 2b portion of its multinational Phase 2b/3 COVID-19 Ifenprodil study sometime during the last week of March 2021.read more >
Algernon Pharmaceuticals reported it is considering adding "lung scarring" as an additional primary endpoint to its Phase 2b/3 COVID-19 Ifenprodil study protocol.read more >
Algernon Pharmaceuticals entered into an agreement with Charles River Laboratories, "a recognized world leader for pre-clinical neurological studies," to conduct preclinical studies for psychedelic compound DMT in stroke patients.read more >
This clinical program of Algernon Pharmaceuticals and upcoming catalysts regarding its in-progress COVID-19 and chronic cough trials are discussed in a Mackie Research Capital Corp. report.read more >
Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, announced that it has established a clinical research program for the treatment of stroke focused on AP-188 (DMT), a known psychedelic compound. Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021.read more >
Algernon Pharmaceuticals reported that it has been granted approval from the Data and Safety Monitoring Board to conduct a Phase 3 Study of Ifenprodil for SARS-CoV-2.read more >
Algernon Pharmaceuticals provided additional interim data from its Phase 2b/3 Ifenprodil COVID-19 study outlining several potential primary endpoints for the Phase 3 portion of the trial.read more >
Learn from Algernon Pharmaceuticals' Christopher J. Moreau, CEO, and Dr. Mark Williams Algernon’s CSO, and guests Dr. Mark Swaim and Steve Palmer as they discuss upcoming catalysts and events.read more >
Algernon Pharmaceuticals reported that interim data from its Phase 2b/3 Ifenprodil COVID-19 study is showing very positive signs of reducing the need for mechanical ventilators.read more >
Algernon Pharmaceuticals reported it has enrolled 154 patients in its Phase 2b/3 human study of Ifenprodil for COVID-19 and is increasing the pool to 168 patients to allow for attrition.read more >
Algernon Pharmaceuticals reported it intends to announce the interim results from its Ifenprodil Phase 2b/3 COVID-19 human study during the first week of December 2020.read more >
Algernon Pharmaceuticals CEO Christopher Moreau and guests fund manager Steve Palmer, Dr. Mark Swaim and Tony Pullen discuss the company's upcoming catalysts and events.
read more >
Algernon Pharmaceuticals reported it has now enrolled 100 of 150 planned patients in its Phase 2b/3 human study of Ifenprodil for treatment of COVID-19.read more >
Algernon Pharmaceuticals reported it has enrolled the first 75 of 150 patients in a multinational Phase 2b/3 human study of Ifenprodil in treating SARS-CoV-2.read more >
Algernon Pharmaceuticals reported it has enrolled the first U.S. patient in its multinational Phase 2b/3 human study of Ifenprodil for use in treatment of SARS-CoV-2.read more >
Algernon Pharmaceuticals reported that the first patient has been dosed in the Phase 2 human study of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough.read more >
Small-cap Algernon Pharmaceuticals is about to begin a multinational Phase 2b/3 trial for Ifenprodil, a repurposed drug with a known safety record.read more >
Algernon Pharmaceuticals received ethics approval in Australia for a Phase 2 human clinical study of NP-120 (Ifenprodil) for use in treatment of idiopathic pulmonary fibrosis and chronic cough.read more >
Algernon Pharmaceuticals reported it received approval from Health Canada for a Phase 2b/3 multinational clinical study of Ifenprodil in COVID-19 patients to prevent progression to intubation and mechanical ventilation.read more >
Algernon Pharmaceuticals will evaluate one of its drugs in coronavirus-infected patients with severe pneumonia.read more >
Expert Comments:
Clive Maund, CliveMaund.com
(4/24/23)
"The case for buying Algernon Pharmaceuticals Inc. here is clear and compelling. . .the company has developed a highly effective product and its stock is silly cheap and so a good investment. There is a good chance for obvious reasons that some larger company will show up and buy Algernon out."
Douglas Loe, Leede Jones Gable
(1/13/23)
"Algernon Pharmaceuticals Inc. intends to initiate a 180-patient Phase 2b trial assessing the company's lead N-methyl-D-aspartate receptor antagonist ifenprodil/NP-120 as a treatment for chronic cough. The firm intends to commence the trial by Q3/23."
Clive Maund, CliveMaund.com
(12/21/22)
"Algernon Pharmaceuticals Inc. has two things going for it. One is that it could come out with positive news at any time that could get the stock moving, and the other is that with only 2.3M shares in issue, when it does move, it is likely to result in big percentage gains. . .the company is therefore rated a Strong Speculative Buy."
Dr. André Uddin, Research Capital Corporation
(11/30/22)
"Positive Phase 2a data was previously achieved with Algernon Pharmaceuticals Inc.'s ifenprodil in idiopathic pulmonary fibrosis and chronic cough. . .we believe management is going to hone most of its efforts on its lead candidate ifenprodil for chronic cough and advance it into Phase 2b trials."
Clive Maund, CliveMaund.com
(10/24/22)
"Algernon Pharmaceuticals Inc. got sold down further than we expected, making an unexpected further drop last week that took it down close to a trend line connecting a series of lows; however the company now looks set to reverse to the upside, especially as this morning it came out with the news that it has entered into a clinical trial agreement with Yale University for a DMT Phase 2 depression study. . .anyone holding should therefore stay long, and Algernon is rated a Buy again here."
Clive Maund, CliveMaund.com
(10/16/22)
"Algernon Pharmaceuticals Inc. has reacted back further than expected with the result that it has arrived back in a zone of strong support where a string of bullish candles has formed since early this month. It is deeply oversold here on its moving average convergence-divergence (MACD) and relative to its moving averages, with the normalizing MACD histogram (bars) calling for a rally soon, especially as we have only seen upside volume in recent days. . .the company is rated an immediate Strong Buy."
More Expert Comments
Clive Maund, CliveMaund.com
(9/27/22)
"One stock viewed as an Immediate Buy here is Algernon Pharmaceuticals Inc. Although it has reacted back heavily in recent weeks following a very strong runup, the reaction is within normal parameters, especially given what happened to the market as a whole; this reaction has brought it back into a zone of support near to its rising 50-day moving average, so that even a minor relief rally in the broad market could see it shoot back up again."
Clive Maund, CliveMaund.com
(8/23/22)
"Algernon Pharmaceuticals Inc. announced the successful closing of its financing, which was oversubscribed. This will lift a restraint from the stock price. . .the company's largest shareholder has upped its stake significantly so that it now owns over 13% of the stock, which is of course a vote of confidence. . .so the case for buying Algernon here could scarcely be stronger. . .this is definitely a stock that is worth going overweight on."
Clive Maund, CliveMaund.com
(8/17/22)
"Given the bright fundamentals, Algernon Pharmaceuticals Inc.'s reaction earlier this week is thought to be about over. . .it is a good time to make fresh purchases as the company is rated Buy again here."
Clive Maund, CliveMaund.com
(8/15/22)
"There is a quite compelling reason to hold out for further gains with Algernon Pharmaceuticals Inc. . .with a relatively tiny number of shares in issue, now believed to be at 1.9M, the company has the capacity to make really big moves, such as occurred last January, which move we traded, so it could continue to spike higher, resistance or not."
Clive Maund, CliveMaund.com
(7/28/22)
"Algernon Pharmaceuticals Inc. came out with very good news this morning that the data from its Phase 2 study of ifenprodil is much better than expected. This is thought likely to get the stock moving again, and so we are considered to be at another good buy spot here."
Dr. André Uddin, Research Capital Corporation
(7/28/22)
"After conducting additional statistical review of the Phase 2a data in idiopathic pulmonary fibrosis (IPF) patients with chronic cough, key opinion leader Dr. Jacky Smith noted that Algernon Pharmaceuticals Inc.'s cough data showed a significant improvement in mean objective 24-hour and waking cough counts after four and 12 weeks. . .it is our belief that it would be logical to develop ifenprodil for two indications: in IPF patients and also in IPF patients who have chronic cough."
Dr. André Uddin, Research Capital Corporation
(7/18/22)
"Algernon Pharmaceuticals Inc. reported topline results of a Phase 2a trial with ifenprodil in idiopathic pulmonary fibrosis (IPF) patients with chronic cough. The IPF data hit its endpoint, showing promising initial efficacy. . .we recommend investors with a higher risk tolerance to aggressively purchase the stock."
Clive Maund, CliveMaund.com
(6/1/22)
"Algernon Pharmaceuticals Inc. is at a very good price and looks like it is shaping up for a breakout into a new bull market. This is a stock that is made much more attractive by the fact that it only has about 1.6M shares in issue as a result of a recent 1 for 100 share rollback. . .the stock is only at about 6% of the price at its 2016 peak."
Clive Maund, CliveMaund.com
(2/2/22)
"We can see entry and exit points on the latest three-month chart of Algernon Pharmaceuticals Inc. stock and how it has reacted back in a satisfactory manner to another good buy spot, with the technical setup now very positive. The time has thus arrived to buy back the position we sold at a much higher price; it is rated a Strong buy again here, especially as the broad stock market is on the up again."
Dr. André Uddin, Research Capital Corporation
(1/28/22)
"For Algernon Pharmaceuticals Inc., the results of the ongoing Phase 2a trial in idiopathic pulmonary fibrosis/chronic cough (Q2/22) represent an important near-term catalyst investors should watch. . .we believe the company is back on track and focused on developing its pipeline. We consider Algernon's current valuation favorable from a risk-reward standpoint."
Clive Maund, CliveMaund.com
(1/19/22)
"As we can see on its latest six-month chart, Algernon Pharmaceuticals Inc.'s stock has soared. . .we have certainly done well with this, having about doubled our money in a month."
Bob Moriarty, 321 Gold
(1/18/22)
"Algernon Pharmaceuticals Inc. has a lot of potential, and I placed my bet with shares bought in the open market. . .the company has a lot of good things in the works, and there should be a constant flow of news. It's the kind of company that could be a $500M market cap in a takeout after success in any one of several drug trials."
Clive Maund, CliveMaund.com
(1/12/22)
"Long-term charts show Algernon Pharmaceuticals Inc. stock to be very cheap. As it now has only 1.6M shares in issue after a 1 for 100 rollback, it has big upside potential. . .the company remains a Buy here and especially on any minor dips, if any."
Clive Maund, CliveMaund.com
(12/22/21)
"Algernon Pharmaceuticals Inc. stock has now arrived at what looks like a long-term cyclical low at the support at its late 2019 lows, which is a good point for it to turn, and that's what it looks like it is in the process of doing. . .the fundamentals of the company are believed to be positive. The conclusion is that Algernon is rated an attractive Speculative Buy here."
Clive Maund, CliveMaund.com
(12/12/21)
"Algernon Pharmaceuticals Inc. has some good things going on. The stock looks like it is at or close to a cyclical low, especially as volume has built up dramatically over the past month in a manner that is characteristic of a bottom, with upside volume kicking in in recent days. . .we could soon see some good gains in this stock."
Dr. André Uddin, Research Capital Corporation
(12/6/21)
"Algernon Pharmaceuticals Inc.'s Ifenprodil is in a Phase 2a trial in idiopathic pulmonary fibrosis/chronic cough. . .the company expects to complete patient enrollment of the study by 2021E, with results anticipated in Q2/22. . .Algernon is a Phase 2-stage drug development company, yet it has a market cap of CA$7M. We believe its risk/reward profile is attractive."
Dr. André Uddin, Research Capital Corporation
(8/4/21)
Algernon Pharmaceuticals Inc. has decided to terminate the development of Ifenprodil for COVID-19. . .we agree with management that the risk-benefit profile of the COVID-19 program does not justify its continuation; we view the company's move as wise. . .Algernon is switching focus to the idiopathic pulmonary fibrosis/chronic cough indication."
Experts Following This Company
Gerard Adams, President & CEO– National Inflation Association
Important Disclosures
Algernon Pharmaceuticals Inc. is a Billboard advertiser of Streetwise Reports and pays a flat fee. Fees fund both sponsor-specific activities and general report activities. Sponsor-specific activities may include aggregating content and publishing that content on the Streetwise Reports site, creating and maintaining company landing pages, interviewing key management, posting a banner/billboard, and/or issuing press releases.
The fees also cover the costs for Streetwise Reports to publish and syndicate investment opinion and comments, and also to curate or create sector-specific content.
Billboard advertising monthly fees range from $3,000 to $5,000.
This landing page contains a summary of the company that was prepared by that company.
Some landing pages contain investing highlights and a catalyst calendar that are prepared by that company.
The Expert Comments and Experts Following This Company sections of the landing page are compiled by Streetwise Reports.
There may be other information about the company that is not placed on the landing page, and Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on the landing page.
Readers should conduct their own research for all information publicly available concerning the company.
This landing page may be considered advertising for the purposes of 18 U.S.C. 1734.
Streetwise Company Fact Sheet
